
CONMED Corporation CNMD
$ 45.89
-0.18%
Annual report 2025
added 02-17-2026
CONMED Corporation Book Value 2011-2026 | CNMD
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value CONMED Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.03 B | 963 M | 834 M | 746 M | 785 M | 709 M | 710 M | 662 M | 631 M | 581 M | 585 M | 581 M | 606 M | 607 M | 573 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.03 B | 573 M | 707 M |
Quarterly Book Value CONMED Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.01 B | 1 B | 978 M | 933 M | 882 M | 855 M | 796 M | 780 M | 752 M | 746 M | 716 M | - | 790 M | 785 M | 756 M | 744 M | 726 M | 709 M | 709 M | 709 M | 709 M | 710 M | 710 M | 710 M | 710 M | 662 M | 662 M | 662 M | 662 M | 631 M | 631 M | 631 M | 631 M | 581 M | 581 M | 581 M | 581 M | 585 M | 585 M | 585 M | 585 M | 581 M | 581 M | 581 M | 581 M | 606 M | 606 M | 606 M | 606 M | 607 M | 607 M | 607 M | 607 M | 573 M | 573 M | 573 M | 573 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.01 B | 573 M | 683 M |
Book Value of other stocks in the Medical devices industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acutus Medical
AFIB
|
-879 K | - | -26.83 % | $ 2.62 M | ||
|
Alphatec Holdings
ATEC
|
791 M | $ 13.94 | -0.71 % | $ 2.09 B | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
ClearPoint Neuro
CLPT
|
25.4 M | $ 14.09 | -7.06 % | $ 381 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
196 M | - | - | $ 1.77 B | ||
|
Apollo Endosurgery
APEN
|
32.6 M | - | - | $ 475 M | ||
|
Lianluo Smart Limited
LLIT
|
272 M | - | 24.59 % | $ 44.8 M | ||
|
Avinger
AVGR
|
-6.2 M | - | -20.74 % | $ 369 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
25.5 M | - | -5.86 % | $ 30.6 M | ||
|
AxoGen
AXGN
|
129 M | $ 31.87 | 2.07 % | $ 1.47 B | ||
|
Cognyte Software Ltd.
CGNT
|
217 M | $ 7.0 | 5.74 % | $ 503 M | ||
|
EDAP TMS S.A.
EDAP
|
40.9 M | $ 4.38 | -4.58 % | $ 163 M | ||
|
Axonics Modulation Technologies
AXNX
|
570 M | - | - | $ 3.31 B | ||
|
Electromed
ELMD
|
43.2 M | $ 24.18 | 1.09 % | $ 204 M | ||
|
Aziyo Biologics
AZYO
|
-38.6 M | - | 1.37 % | $ 20.5 M | ||
|
Apyx Medical Corporation
APYX
|
26.9 M | $ 3.49 | 2.05 % | $ 121 M | ||
|
Conformis
CFMS
|
54.2 M | - | - | $ 16.4 M | ||
|
Bio-Rad Laboratories
BIO
|
6.57 B | $ 275.33 | 2.19 % | $ 7.77 B | ||
|
BIOLASE
BIOL
|
1.96 M | - | -13.19 % | $ 166 K | ||
|
Bruker Corporation
BRKR
|
1.82 B | $ 40.88 | 2.48 % | $ 6.09 K | ||
|
BioSig Technologies
BSGM
|
-1.42 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
43.7 B | $ 75.65 | 2.97 % | $ 112 B | ||
|
InMode Ltd.
INMD
|
683 M | $ 14.0 | 0.29 % | $ 905 M | ||
|
IRIDEX Corporation
IRIX
|
9.52 M | $ 1.47 | -2.0 % | $ 23.7 M | ||
|
IRadimed Corporation
IRMD
|
86.8 M | $ 102.4 | 1.89 % | $ 1.3 B | ||
|
CryoLife, Inc.
CRY
|
58.1 M | - | -4.14 % | $ 702 M | ||
|
CHF Solutions, Inc.
CHFS
|
6.23 M | - | 1.15 % | $ 34.5 M | ||
|
Soliton, Inc.
SOLY
|
243 M | - | -1.42 % | $ 435 M | ||
|
Cardiovascular Systems
CSII
|
249 M | - | 0.15 % | $ 844 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
2.61 B | - | -1.98 % | $ 98.3 M | ||
|
LivaNova PLC
LIVN
|
1.2 B | $ 71.26 | 1.38 % | $ 3.89 B | ||
|
Itamar Medical Ltd.
ITMR
|
229 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
30.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
52.2 M | - | - | $ 111 M | ||
|
Cutera
CUTR
|
-172 M | - | -10.19 % | $ 1.99 M | ||
|
Medtronic PLC
MDT
|
48.3 B | $ 97.22 | 0.58 % | $ 125 B | ||
|
Delcath Systems
DCTH
|
68.7 M | $ 9.11 | -10.77 % | $ 260 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
189 M | $ 2.48 | 1.02 % | $ 146 M | ||
|
Intersect ENT, Inc.
XENT
|
550 M | - | - | $ 955 M | ||
|
Dynatronics Corporation
DYNT
|
3.26 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
101 M | - | - | $ 10.2 M | ||
|
Second Sight Medical Products
EYES
|
17.6 M | - | -0.97 % | $ 54.4 M | ||
|
Establishment Labs Holdings
ESTA
|
53.1 M | $ 77.41 | -1.12 % | $ 2.18 B | ||
|
Insulet Corporation
PODD
|
1.52 B | $ 251.74 | 1.46 % | $ 17.7 B | ||
|
Quanterix Corporation
QTRX
|
347 M | $ 6.7 | 6.52 % | $ 252 M | ||
|
GBS
GBS
|
2.81 M | - | -0.57 % | $ 7.12 M | ||
|
FONAR Corporation
FONR
|
146 M | $ 18.53 | -0.3 % | $ 121 M | ||
|
Sintx Technologies
SINT
|
8.77 M | $ 2.89 | -1.87 % | $ 10.8 M | ||
|
MiMedx Group
MDXG
|
257 M | $ 4.97 | -5.78 % | $ 735 M |